Is Cell Point overvalued or undervalued?

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all suggesting that the stock is priced significantly higher than its earnings potential.
In comparison to its peers, Cell Point's valuation appears particularly high when contrasted with PTC India, which has a PE ratio of 7.52 and is rated as very attractive, and Optiemus Infra, rated as fair with a PE of 75.09. This stark difference in valuation metrics underscores the overvaluation of Cell Point. Additionally, while the stock has shown a recent one-week return of 8.33% compared to the Sensex's 1.64%, its year-to-date performance is concerning, with a decline of 27.1% against a 9.58% rise in the Sensex, further reinforcing the notion that Cell Point is not a favorable investment at its current price.